Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma

JAMA

Volumn 307, Issue 24, 2012, Pages 2609-2616

  Metzger, Monika L ^a,b   Weinstein, Howard J ^a,c   Hudson, Melissa M ^a,b   Billett, Amy L ^a,d,e   Larsen, Eric C ^a,f   Friedmann, Alison ^a,c   Howard, Scott C ^a,b   Donaldson, Sarah S ^a,g   Krasin, Matthew J ^a   Kun, Larry E ^a   Marcus, Karen J ^a,d,e   Yock, Torunn I ^a,c   Tarbell, Nancy ^a,c   Billups, Catherine A ^a   Wu, Jianrong ^a   Link, Michael P ^a,g  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Barbara Bush Children's Hospital   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; METHOTREXATE; PREDNISONE; VINBLASTINE;

ADULT; ARTICLE; BONE NECROSIS; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE FAILURE; HODGKIN DISEASE; HUMAN; LUNG DISEASE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; OSTEOPENIA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 84862841215     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.5847     Document Type: Article

References (37)

1. Hudson MM, Jones D, Boyett J, Sharp GB, Pui CH. Late mortality of long-term survivors of childhood cancer. J Clin Oncol. 1997;15(6):2205-2213. (Pubitemid 27251120)
2. Hudson MM, Poquette CA, Lee J, et al. Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol. 1998;16(11):3592-3600. (Pubitemid 28506773)
3. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2011;117(6):1806-1816.
4. DörffelW, Lüders H, Rühl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr. 2003; 215(3):139-145. (Pubitemid 36718285)
5. Mauz-Körholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010; 28(23):3680-3686.
6. Donaldson SS, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with lowrisk Hodgkin's disease. J Clin Oncol. 2007;25(3): 332-337. (Pubitemid 350003023)
7. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: responseadapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18(7): 1500-1507. (Pubitemid 30205396)
8. Tebbi CK, Mendenhall N, London WB, Williams JL, de Alarcon PA, Chauvenet AR. Treatment of stage I, IIA, IIIA(1) pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study. Pediatr Blood Cancer. 2005;46(2):198-202. (Pubitemid 43076071)
9. Kung FH, Schwartz CL, Ferree CR, et al Children's Oncology Group. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children's Oncology Group. J Pediatr Hematol Oncol. 2006;28(6):362-368. (Pubitemid 43970392)
10. Schwartz CL, Constine LS. Early response-based therapy for children with hodgkin lymphoma: a surrogate for using biology to effect cure and minimize toxicity. In: 2010 Educational Book. Alexandria, VA: American Society of Clinical Onocologists; 2010: 391-396.
11. Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescentswith favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol. 2002;20(14):3081-3087. (Pubitemid 34791097)
12. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31(11):1860-1861.
13. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019-5032.
14. Brepoels L, Stroobants S, De Wever W, et al. Hodgkin lymphoma: response assessment by revised International Workshop Criteria. Leuk Lymphoma. 2007; 48(8):1539-1547. (Pubitemid 47272804)
15. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965;52:203-223.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53:457-481.
17. Cox DR. Regression models and life-tables. J R Stat Soc, B. 1972;34:187-220.
18. Hudson MM, Greenwald C, Thompson E, et al. Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease. J Clin Oncol. 1993; 11(1):100-108. (Pubitemid 23059982)
19. Hunger SP, Link MP, Donaldson SS. ABVD/MOPPand low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience. J Clin Oncol. 1994;12(10):2160-2166. (Pubitemid 24356035)
20. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVDwith or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1997;15(8):2769-2779. (Pubitemid 27330002)
21. Behrendt H, Brinkhuis M, Van Leeuwen EF. Treatment of childhood Hodgkin's disease with ABVD without radiotherapy. Med Pediatr Oncol. 1996;26 (4):244-248. (Pubitemid 26076172)
22. Hakvoort-Cammel FG, Buitendijk S, van den Heuvel-Eibrink M, Hählen K. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol. Pediatr Blood Cancer. 2004;43(1):8-16. (Pubitemid 38738266)
23. van den Berg H, Zsiros J, Behrendt H. Treatment of childhood Hodgkin's disease without radiotherapy. Ann Oncol. 1997;8(suppl 1):15-17.
24. Baez F, Ocampo E, Conter V, et al. Treatment of childhood Hodgkin's disease with COPP or COPPABV (hybrid) without radiotherapy in Nicaragua. Ann Oncol. 1997;8(3):247-250. (Pubitemid 27153490)
25. Jacobs P, King HS, Karabus C, Hartley P, Werner D. Hodgkin's disease in children: a ten-year experience in South Africa. Cancer. 1984;53(2):210-213. (Pubitemid 14180729)
26. Olweny CL, Katongole-Mbidde E, Kiire C, Lwanga SK, Magrath I, Ziegler JL. Childhood Hodgkin's disease in Uganda: a ten year experience. Cancer. 1978; 42(2):787-792. (Pubitemid 8406612)
27. Donaldson SS, Link MP. Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol. 1987;5(5):742-749. (Pubitemid 17120251)
28. Friedmann AM, Hudson MM, Weinstein HJ, et al. Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol. 2002;20(14):3088-3094. (Pubitemid 34791098)
29. Hudson MM, Krasin M, Link MP, et al. Riskadapted, combined-modality therapy with VAMP/ COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol. 2004;22(22):4541-4550. (Pubitemid 41185121)
30. Nachman JB, Sposto R, Herzog P, et al Children's Cancer Group. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20(18):3765-3771.
31. Nogová L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16(10):1683-1687. (Pubitemid 41510144)
32. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocytepredominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104(6):1221-1229. (Pubitemid 41278957)
33. Karayalcin G, Behm FG, Gieser PW, et al. Lymphocyte predominant Hodgkin disease: clinicopathologic features and results of treatment-the Pediatric Oncology Group experience. Med Pediatr Oncol. 1997;29(6):519-525. (Pubitemid 27419402)
34. Murphy SB, Morgan ER, Katzenstein HM, Kletzel M. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol. 2003;25 (9):684-687. (Pubitemid 37087503)
35. Sandoval C, Venkateswaran L, Billups C, Slim M, Jayabose S, Hudson MM. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol. 2002;24(4):269-273. (Pubitemid 34506613)
36. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483-3489. (Pubitemid 39564416)
37. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer. 2007;110: 179-185. (Pubitemid 46986431)